SAN DIEGO, Aug. 5 /PRNewswire-FirstCall/ -- CardioDynamics , the innovator and leader of BioZ(R) impedance cardiography (ICG) technology, today announced that the Company’s BioZ(R) Dx now seamlessly integrates with General Electric Healthcare’s Centricity(R) electronic medical record (EMR) system.
The Company released this week its latest version of BioZport(R) ICG data management software which includes capabilities to automatically integrate and transfer BioZ(R) ICG data from the BioZ(R) Dx to GE Healthcare’s Centricity(R) EMR system. This is a strategic advancement for the Company’s flagship product as EMR interface and paperless workflow are increasingly becoming necessities to the outpatient physician when making decisions on new medical technologies. Currently, it is estimated that 24% of U.S. outpatient physicians utilize an EMR system. Medical device to EMR interface capability will continue to grow in importance as U.S. outpatient-based physician use of EMR is forecasted to grow at over 16% per year through 2013.
Michael K. Perry, CardioDynamics Chief Executive Officer, stated, “We are extremely pleased to release our initial BioZ ICG direct EMR interface. EMR is a driving, essential factor in the majority of medical device decisions for early adopter physicians and large physician practices. Interfacing with our long-time partner, GE Healthcare, whose Centricity(R) system has nearly 10% share in our sizable outpatient physician market, is a great accomplishment for our company, customers, prospective customers and investors.”
Perry continued, “Our EMR strategy is to partner with the top 10% to 15% of EMR suppliers, who collectively have 80% of U.S. outpatient market share. Allscripts, the second largest outpatient EMR provider, with over 12% market share, is our next planned interface. With increasing penetration rates for both ICG and EMR, interface capability should further accelerate the adoption of ICG and supports our long-term vision that BioZ ICG is present in every physician office that prescribes cardiovascular medicine for heart failure, shortness of breath and high blood pressure patients.”
BioZ ICG technology presently resides in approximately one out of every six (16%) cardiology offices as well as one out of every five (20%) outpatient heart failure clinics in the United States with over one million BioZ tests performed annually.
For further information, please contact Emma Brejwo at ebrejwo@cdic.com.
About CardioDynamics:
CardioDynamics , the ICG Company, is the innovator and leader of an important medical technology called BioZ(R) Impedance Cardiography (ICG). The Company develops, manufactures and markets noninvasive BioZ(R) ICG products and medical device electrodes. The Company’s BioZ(R) ICG Systems are being used by physicians around the world to help battle the number one killer of men and women -- cardiovascular disease. Partners include GE Healthcare, Philips Medical Systems, and Mindray. For additional information, please refer to the company’s Web site at http://www.cdic.com.
Forward-Looking (Safe Harbor) Statement:
Except for the historical and factual information contained herein, this press release contains forward-looking statements, the accuracy of which is necessarily subject to uncertainties and risks including the Company’s sole dependence on the BioZ(R) product line, and various uncertainties characteristic of early growth companies, as well as other risks detailed in the Company’s filings with the SEC, including its 2007 Form 10-K. The Company does not undertake to update the disclosures contained in this press release.
CONTACT: Emma Brejwo, Investor Relations Associate of CardioDynamics,
1-800-778-4825, Ext. 1031, ebrejwo@cardiodynamics.com
Web site: http://www.cdic.com/
